Literature DB >> 9891154

CT visualization of blood pool in rats by using long-circulating, iodine-containing micelles.

V P Torchilin1, M D Frank-Kamenetsky, G L Wolf.   

Abstract

RATIONALE AND
OBJECTIVES: Small, long-circulating particulate carriers of contrast agents, such as micelles, are potentially useful in computed tomographic (CT) blood-pool imaging. An iodine-containing amphiphilic block-copolymer consisting of iodine-substituted poly-L-lysine (MPEG-iodolysine) forms micelles in an aqueous solution. The biodistribution and CT depiction of these radiopaque micelles were therefore studied in rats.
MATERIALS AND METHODS: MPEG-iodolysine micelles were synthesized and injected into rats via the tail vein at a dose of 170 mg iodine per kilogram. Three animals were used, and tissue enhancement was followed on serial CT scans.
RESULTS: MPEG-iodolysine block-copolymer forms particulates with an average diameter of 80 nm and an iodine content of 33.8%. After intravenous injection into rats, the agent produced noticeable and sustained enhancement of the blood pool (aorta and heart), liver, and spleen for least 3 hours.
CONCLUSION: In rats, MPEG-iodolysine micelles were a long-lived blood-pool contrast agent useful for CT.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9891154     DOI: 10.1016/s1076-6332(99)80063-4

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  30 in total

Review 1.  Anatomical and microstructural imaging of angiogenesis.

Authors:  Fabian Kiessling; Daniel Razansky; Frauke Alves
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08       Impact factor: 9.236

Review 2.  Design and pharmacokinetical aspects for the use of inorganic nanoparticles in radiomedicine.

Authors:  Victor Puntes
Journal:  Br J Radiol       Date:  2015-10-23       Impact factor: 3.039

3.  Time-course of contrast enhancement in spleen and liver with Exia 160, Fenestra LC, and VC.

Authors:  Inneke Willekens; Tony Lahoutte; Nico Buls; Christian Vanhove; Rudi Deklerck; Axel Bossuyt; Johan de Mey
Journal:  Mol Imaging Biol       Date:  2008-12-06       Impact factor: 3.488

Review 4.  Nanotechnology for computed tomography: a real potential recently disclosed.

Authors:  Nicolas Anton; Thierry F Vandamme
Journal:  Pharm Res       Date:  2013-07-30       Impact factor: 4.200

Review 5.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

6.  Biodegradable iodinated polydisulfides as contrast agents for CT angiography.

Authors:  Erlei Jin; Zheng-Rong Lu
Journal:  Biomaterials       Date:  2014-04-24       Impact factor: 12.479

7.  Anatomical and functional imaging of myocardial infarction in mice using micro-CT and eXIA 160 contrast agent.

Authors:  Jeffrey R Ashton; Nicholas Befera; Darin Clark; Yi Qi; Lan Mao; Howard A Rockman; G Allan Johnson; Cristian T Badea
Journal:  Contrast Media Mol Imaging       Date:  2014 Mar-Apr       Impact factor: 3.161

Review 8.  Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies.

Authors:  Benjamin M Yeh; Paul F FitzGerald; Peter M Edic; Jack W Lambert; Robert E Colborn; Michael E Marino; Paul M Evans; Jeannette C Roberts; Zhen J Wang; Margaret J Wong; Peter J Bonitatibus
Journal:  Adv Drug Deliv Rev       Date:  2016-09-09       Impact factor: 15.470

9.  Poly(ethylene glycol)-poly(ε-caprolactone) iodinated nanocapsules as contrast agents for X-ray imaging.

Authors:  François Hallouard; Stéphanie Briançon; Nicolas Anton; Xiang Li; Thierry Vandamme; Hatem Fessi
Journal:  Pharm Res       Date:  2013-04-26       Impact factor: 4.200

Review 10.  Polymeric micelles in anticancer therapy: targeting, imaging and triggered release.

Authors:  Chris Oerlemans; Wouter Bult; Mariska Bos; Gert Storm; J Frank W Nijsen; Wim E Hennink
Journal:  Pharm Res       Date:  2010-08-20       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.